CN106262809A - 一种增强骨密度缓解中老年关节疼痛的组合物 - Google Patents
一种增强骨密度缓解中老年关节疼痛的组合物 Download PDFInfo
- Publication number
- CN106262809A CN106262809A CN201610621668.7A CN201610621668A CN106262809A CN 106262809 A CN106262809 A CN 106262809A CN 201610621668 A CN201610621668 A CN 201610621668A CN 106262809 A CN106262809 A CN 106262809A
- Authority
- CN
- China
- Prior art keywords
- calcium
- compositions
- parts
- arthralgia
- person
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 208000006820 Arthralgia Diseases 0.000 title claims abstract description 39
- 230000037182 bone density Effects 0.000 title claims abstract description 16
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims abstract description 38
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000011575 calcium Substances 0.000 claims abstract description 32
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 32
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 31
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 31
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 31
- 244000068988 Glycine max Species 0.000 claims abstract description 30
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 26
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 24
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960002442 glucosamine Drugs 0.000 claims abstract description 16
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 15
- 238000010521 absorption reaction Methods 0.000 claims abstract description 15
- 230000017531 blood circulation Effects 0.000 claims abstract description 15
- 239000008280 blood Substances 0.000 claims abstract description 14
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- 230000001737 promoting effect Effects 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 235000019596 Masking bitterness Nutrition 0.000 claims abstract description 8
- 229940069978 calcium supplement Drugs 0.000 claims abstract description 6
- 239000003623 enhancer Substances 0.000 claims abstract description 6
- 238000005728 strengthening Methods 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 229960005069 calcium Drugs 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 19
- 241000628997 Flos Species 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 13
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 11
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 11
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 11
- 239000001527 calcium lactate Substances 0.000 claims description 11
- 229960002401 calcium lactate Drugs 0.000 claims description 11
- 235000011086 calcium lactate Nutrition 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 11
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 11
- 239000000811 xylitol Substances 0.000 claims description 11
- 235000010447 xylitol Nutrition 0.000 claims description 11
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 11
- 229960002675 xylitol Drugs 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229960002849 glucosamine sulfate Drugs 0.000 claims description 6
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 3
- 241000180649 Panax notoginseng Species 0.000 claims description 3
- 239000004227 calcium gluconate Substances 0.000 claims description 3
- 229960004494 calcium gluconate Drugs 0.000 claims description 3
- 235000013927 calcium gluconate Nutrition 0.000 claims description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical group [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- 229960004256 calcium citrate Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 claims 1
- 235000001465 calcium Nutrition 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 17
- 210000000629 knee joint Anatomy 0.000 abstract description 13
- 206010003246 arthritis Diseases 0.000 abstract description 11
- 210000003205 muscle Anatomy 0.000 abstract description 10
- 239000013589 supplement Substances 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 230000007170 pathology Effects 0.000 abstract description 3
- 229960003487 xylose Drugs 0.000 description 17
- 210000000845 cartilage Anatomy 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 8
- 102000055008 Matrilin Proteins Human genes 0.000 description 7
- 108010072582 Matrilin Proteins Proteins 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 6
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000001050 lubricating effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000003797 carpal joint Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 125000000600 disaccharide group Chemical group 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000002301 glucosamine derivatives Chemical class 0.000 description 2
- -1 glucosamine hydrochloric acid Salt Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- USDAQJSRGJCNNX-FLGKMABCSA-N NC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO.S(O)(O)(=O)=O Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO.S(O)(O)(=O)=O USDAQJSRGJCNNX-FLGKMABCSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000004263 amino monosaccharides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940065133 calcium carbonate 1000 mg Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002078 massotherapy Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种增强骨密度缓解中老年关节疼痛的组合物。该组合物的组分及重量份为:大豆肽5~10份、硫酸软骨素0.2~0.5份、氨基葡萄糖或其盐0.5~1.5份、低聚木糖0.7~3份、钙吸收促进剂及钙质补充剂0.8‑1.3份、活血化瘀性质中药提取物0.5‑3份、大豆肽苦味掩盖剂3‑10份。本发明的组合物,对于“膝关节骨性关节炎”发生原因,针对性解决各项病理成因,通过硫酸软骨素缓解病痛,并通过增强肌肉,加速血液流通、补充钙质,防止钙流失来达到缓解关节疼痛达到预防和/治疗骨关节疼痛的目的。
Description
技术领域
本发明涉及食品及保健品加工领域,涉及一种通过增强骨密度活血化瘀来缓解中老年关节疼痛产品,具体涉及一种增强骨密度缓解中老年关节疼痛的组合物。
背景技术
膝关节骨性关节炎,又称膝关节退行性关节炎,是中老年人膝关节疼痛的最常见原因。膝关节表面覆有一层软骨,这层软骨可以起到保护其下骨质和神经的作用。随着关节使用年限的增加,软骨逐渐磨损,软骨下的神经暴露,此时一旦遇到刺激(如上下楼等活动致破损区关节面相互摩擦)便会引起疼痛。此外,遗传也是一个重要的影响因素。膝关节骨性关节炎的症状可表现为单膝疼痛、双膝疼痛或二者交替出现。疼痛于长时间活动时加重,上、下楼时明显,休息后可缓解。查体可见膝关节肿胀,关节局部压痛,屈伸活动受限,有时可感觉到弹响或骨摩擦音,同时还会出现关节周围肌肉萎缩无力。
目前治疗膝关节炎的方法主要有:保守治疗、封闭针治疗、手术治疗(包括微创)和药物疗法四种。保守疗法:包括口服止痛药、推拿和热疗等,药物多以止痛药为主,能够快速的缓解疼痛,不过无法缓解和控制膝关节炎的症状,其中口服止痛药还会严重损伤患者肠胃;封闭针治疗:封闭针治疗法,通常是人工注射一些注射液,注射液的成分为透明质酸或者同类药物和止痛药的混合,主要功能为快速止痛,补充关节炎润滑关节,可以暂时控制症状,无法逆转病变;手术治疗:手术治疗分为普通手术和微创两种,前者创伤大、并发症多;后者创伤较小、并发症也较小,手术治疗能够有效的控制病情恶化,但无法逆转病情,并且有着不小的风险;药物疗法,较为常规的为氨糖作为营养补充剂的疗法,根据骨关节炎形成的根本原因,通过外源性的补充氨糖,补充关节软骨合成必要营养,帮助重新长出正常的关节软骨。
现有技术也公开了多种用于治疗和/缓解中老年关节疼痛的组合物,如专利CN103100017B按照中医理念指出肝肾亏虚,筋骨失养,闭阻经络,气血不能畅行,是造成筋骨和关节疼痛的主要因素,因而根据这一理念提供了一组中药组合物来进行筋骨疼痛、关节疼痛的缓解治疗,但这一中药组合物更多倾向于缓解关节疼痛,对于后续的预防和治疗效果较差。氨基葡萄糖加硫酸软骨素的组合治疗,可减缓关节软骨的磨损,促进软骨修复,从而阻止骨关节炎的进一步恶化,改善关节活动,减少疼痛;但该组合治疗对于缓解疼痛起效慢,后续的预防和治疗效果也有待进一步提高。
进一步开发对于中老年关节疼痛缓解起效快、预防和/治疗效果良好的产品,仍是本领域技术人员面临的难题。
发明内容
针对现有技术中存在的问题,本发明根据中西医结合的理念,考虑“膝关节骨性关节炎”发生原因,结合缓解和预防/治疗的目的,提供一种增强骨密度缓解中老年关节疼痛的组合物。
具体的,本发明涉及以下技术方案:
首先,本发明提供一种增强骨密度缓解中老年关节疼痛的组合物,该组合物的组分及重量份为:
大豆肽5~10份、硫酸软骨素0.2~0.5份、氨基葡萄糖或其盐0.5~1.5份、低聚木糖0.7~3份、钙吸收促进剂及钙质补充剂0.8-1.3份、活血化瘀性质中药提取物0.5-3份、大豆肽苦味掩盖剂3-10份。
大豆肽:也称大豆多肽,是大豆蛋白质的酶解产物,通常为2-10个氨基酸组成的肽类混合物,其分子量主要集中在1000以下,具有降血脂、易消化、易吸收、促进能量代谢、消除疲劳、增强肌肉伸缩及抗过敏、迅速给肌体补充能量、恢复体力,明显地使肌肉疲劳迅速消除,恢复体力。
氨基葡萄糖:是一种天然的氨基单糖,是软骨基质和滑液中聚氨基葡萄糖的成分之一;补充外源性的氨基葡萄糖,除了提供体内合成糖胺多糖的二糖单位的前体外,还可以刺激软骨细胞合成蛋白多糖和胶原蛋白,补充软骨基质的丢失成分,并可抑制基质金属蛋白酶的表达,从而保持软骨基质的正常代谢,促进软骨的修复;此外,氨基葡萄糖可以通过清除自由基,发挥抗炎效应,减轻软骨的损害,临床试验结果显示,氨基葡萄糖不仅对骨关节炎具有症状改善作用,而且还具有改善病程、延缓骨关节炎的关节结构破坏的作用。
硫酸软骨素(Chondroitin Sulfate):是一种高度亲水性、凝胶状大分子多糖,由葡萄糖醛酸和硫酸氨基半乳糖组成的二糖单位重复连接而成;硫酸软骨素能与胶原纤维相连接,稳定软骨基质;除了作为软骨基质的构成成分以外,硫酸软骨素还可通过以下两个机制来治疗骨关节炎:①竞争性抑制降解酶的活性,减少软骨基质和关节滑液成分的破坏;②减少纤维蛋白血栓的形成,平衡血栓形成的倾向,正常生理情况下,随着年龄的增加,人体的硫酸软骨素产量会逐渐减少,被活性较低的硫酸角质素取代,从而容易形成血栓阻塞血管,加重骨关节炎的病理。
氨基葡萄糖盐:现有的用于改善关节问题的氨基葡萄糖盐,包括氨基葡萄糖盐酸盐、氨基葡萄糖硫酸盐等。
低聚木糖:可以促进钙吸收,主要表现为低聚木糖在大肠中被双歧杆菌分解利用并产生短链脂肪酸(乳酸、乙酸、丙酸、丁酸)等,从而使肠道呈酸性环境,短链脂肪酸和钙形成可溶性钙盐,增加钙的溶解并使钙处于易于吸收的离子形式,同时有益微生物产生的氨基酸、维生素可以增加钙的转运,进而促进钙的吸收。
钙吸收促进剂:用于促进钙质的吸收,包括维生素D、乳糖、赖氨酸等。
钙质补充剂:如葡萄糖酸钙、碳酸钙、乳酸钙、柠檬酸钙等。
活血化瘀性质中药提取物:如红花提取物、三七提取物、川芎提取物等。
大豆肽苦味掩盖剂:因大豆肽为大豆的蛋白酶水解物,其不可避免的会产生苦味,通过添加适量苦味掩盖剂可达到降低苦味阈值的目的,阿拉伯糖、木糖醇、柠檬酸、苹果酸等都可用作大豆肽苦味掩盖剂。
本发明针对缓解和预防/治疗中老年关节疼痛的目的需求,考虑西医中“膝关节骨性关节炎”发生原因,将中西医治疗理念结合,提出了本发明所述物质组合。
首先,针对“膝关节骨性关节炎”的发生原因:软骨破坏、骨质疏松与损坏、关节周围肌肉萎缩无力、血液循环差等,发明人综合考虑了这几大因素,提出了能同时改善和/解决这些问题的物质的组合,实现了功能的互补。硫酸软骨素和氨基葡萄糖的组合,可以保护并强化软骨结构、制造蛋白多糖润滑关节、促进软骨基质的修复和重建、抑制软骨的破坏;钙吸收促进剂及钙质补充剂,通过补充钙质,提升骨钙、骨密度含量,减少骨质疏松与损坏倾向;大豆肽,可以促进能量代谢、促进肌红蛋白恢复,有效增强肌肉的活力和耐力,改善关节肌无力症状;活血化瘀性质的中药提取物,如红花提取物,可以有效的活血通络、散瘀止痛,通过改善骨内外血液循环,有效地促进骨修复。
其次,本发明组分的筛选,不仅仅考虑功能的互补,而且实现了组分与功能的协同增效。(1)对于缓解关节疼痛,本发明活血化瘀性质的中药提取物,如红花提取物,可以快速有效的发挥缓解作用,短时间内降低疼痛感,同时硫酸软骨素和氨基葡萄糖随着吸收和代谢的进行,在长时间内延缓骨关节疼痛的病理过程和疾病的进程,改善关节活动,缓解疼痛;(2)对于改善血液循环,除了活血通络性质的中药提取物(如红花提取物)外,本发明的大豆肽也起到改善血管通透性的作用,两者相互促进,进一步改善通络效果;(3)对于各组分的吸收,本发明除了通过常规钙促进吸收剂(如维生素D)促进钙质吸收外,还采用低聚木糖,进一步的改善钙吸收效果,有效的提升了增强骨密度的效果;同时本发明采用低聚木糖和大豆肽共同来改善胃肠环境(大豆肽可以促进微生物生长发育,调节改善胃肠功能,尤其对于双歧杆菌具有良好的促进作用),这对于中老年人,尤其是老年人在利用本发明的组合物时起到良好的适用性改善作用;(4)本发明的组合物可以有效的降低炎症时细胞因子和自由基的损害,大豆肽具有抗氧化作用,可以消除人体自由基,防止新的自由基形成,而且可以抑制ACE活性,氨基葡萄糖同时起到清除自由基,发挥抗炎效应的作用;(5)对于软骨破坏的抑制,硫酸软骨素可以抑制破坏软骨的胶原酶、弹性蛋白酶和组织蛋白酶等,以免软骨被分解或溶解或者硬化,而红花提取物可以抑制破骨细胞的形成,有效的保护骨组织。
再者,本发明所述组分之间可以协同作用,抑制/抵消其他组分所产生的副作用。氨基葡萄糖,尤其是氨基葡萄糖盐酸盐的吸收利用,会造成轻度的胃肠不适,如恶心、便秘、腹胀和腹泻等,通过大豆肽、低聚木糖的使用,可有减缓该不适,改善胃肠作用。
针对上述增强骨密度缓解中老年关节疼痛的组合物,优选的实施例中,组合物的组分及重量份为:大豆肽5~10份、硫酸软骨素0.2~0.5份、硫酸氨基葡萄糖0.5~1.5份、低聚木糖0.7~3份、维生素D 0.8-3×10-5份、乳酸钙0.8-1.2份、红花提取物0.5-3份、阿拉伯糖0.5~1.5份、木糖醇3~8份。
其次,本发明提供上述组合物在制备缓解和/预防或治疗中老年关节疼痛的食品、药品或保健品中的应用。
进一步的,本发明提供一种缓解和/预防或治疗中老年关节疼痛的食品,所述食品的有效成分为上述组合物。
本发明提供一种缓解和/预防或治疗中老年关节疼痛的保健品,所述保健品的有效成分为上述组合物。
本发明提供一种缓解和/预防或治疗中老年关节疼痛的药品,所述药品的有效成分为上述组合物。
所述保健品或药品,除有效成分外,还可以包括常规的辅料成分,如硬脂酸镁、羧甲基纤维素钠、二氧化硅、滑石粉、聚乙二醇、微晶纤维素等;所述保健品或药品可制成液体冲剂、粉剂、片剂或胶囊剂等常规剂型。
本发明取得了以下有益效果:
(1)本发明针对“膝关节骨性关节炎”产生因素,综合考虑,针对性解决各项病理成因,通过硫酸软骨素缓解病痛,并通过增强肌肉,加速血液流通、补充钙质,防止钙流失来达到缓解关节疼痛达到预防和/治疗骨关节疼痛的目的。
(2)强化软骨结构,润滑关节及维持关节功能,预防关节功能失效。本发明中具有硫酸软骨素和氨基葡萄糖可制造蛋白多糖润滑关节,防止骨关节摩擦疼痛,使关节活动自如;同时可以保护并强化软骨结构,预防因关节老化而产生的关节功能失效。
(3)大豆肽作为肌肉增强剂,提高中老年人群肌肉强度;添加乳酸钙与低聚木糖,协同辅助中老年钙质吸收,增强骨密度;可以明显缓解改善中老年人关节疼痛。
(4)本发明从缓解关节疼痛的表征入手,改善关节疼痛的因素——通过补充钙质来避免钙质流失、增强肌肉活力避免肌肉无力加重关节磨损,有效的缓解了老年人关节疼痛。
(5)通过添加低聚木糖、苦味掩盖剂(阿拉伯糖、木糖醇)等,可以明显改善大豆肽的苦涩味;并且通过大豆肽、低聚木糖等,明显改善胃肠状态,有效的促进组合物有效成分吸收。
具体实施方式
实施例1
大豆肽5g、硫酸软骨素0.5g、硫酸氨基葡萄糖0.5g、低聚木糖3g、阿拉伯糖1.5g、木糖醇3g、Vd 10μg、乳酸钙800mg、红花提取物0.5g,混合配成粉剂,>70℃水冲服,每日1~2次。
实施例2
大豆肽10g、硫酸软骨素0.5g、硫酸氨基葡萄糖1.5g、低聚木糖3g、阿拉伯糖1.5g、木糖醇8g、Vd 30μg、乳酸钙1200mg、红花提取物1.5g、硬脂酸镁、羧甲基纤维素钠,压制成片剂10片,每片2g,每次2片,一日3次,最多不超过10片。
实施例3
大豆肽8g、硫酸软骨素0.5g、硫酸氨基葡萄糖1.5g、低聚木糖3g、阿拉伯糖0.5g、Vd20μg、乳酸钙1200mg、红花提取物2g,每0.35g封装成胶囊,每日服用两次,早晚各3粒。
实施例4
大豆肽5g、硫酸软骨素0.5g、氨基葡萄糖盐酸盐0.8g、低聚木糖3g、阿拉伯糖1.5g、木糖醇3g、Vd 10μg、葡萄糖酸钙1200mg、川芎提取物0.6g,混合配成粉剂。
实施例5
大豆肽10g、硫酸软骨素0.2g、硫酸氨基葡萄糖1.5g、低聚木糖1g、木糖醇8g、Vd 30μg、碳酸钙1000mg、川芎提取物1.5g、硬脂酸镁、羧甲基纤维素钠,压制成片。
实施例6
大豆肽8g、硫酸软骨素0.5g、氨基葡萄糖盐酸盐1.5g、低聚木糖3g、阿拉伯糖0.5g、木糖醇8g、Vd 20μg、乳酸钙1200mg、三七提取物2g,每0.35g封装成胶囊。
对比例1
硫酸软骨素0.5g、氨基葡萄糖盐酸盐0.8g、低聚木糖3g、阿拉伯糖1.5g、木糖醇3g、Vd 10μg、乳酸钙800mg、红花提取物0.5g,混合配成粉剂。
对比例2
大豆肽5g、硫酸软骨素0.5g、氨基葡萄糖盐酸盐0.8g、阿拉伯糖1.5g、木糖醇3g、乳酸钙1200mg、红花提取物0.5g,混合配成粉剂。
对比例3
大豆肽1g、硫酸软骨素0.1g、氨基葡萄糖盐酸盐0.1g、低聚木糖0.2g、阿拉伯糖1.5g、木糖醇3g、Vd 10μg、乳酸钙1200mg、红花提取物0.2g,混合配成粉剂。
实施例7动物实验:
将出生4周后雄性断乳大鼠体重60-80g,每组10只,共60只,用低钙饲料饲喂,同时采用实施例1配方10倍剂量组和实施例1、对比例1-3剂量组,用去离子水溶解样品,经口灌胃给予受试动物,灌胃量为1mL/100g,每天1次,喂养4周。
毒性实验结果:灌胃给药后观察四周,均未发现实验动物死亡,本发明的组合物急性毒性低;测定各项指标,观察和测定项目包括如外观体症和行为活动、分泌物、粪便性状,血液的常规指标和生化指标,系统尸检及脏器系数和组织学检查等内容,结果表明:用不同剂量给大鼠连续口服,对大鼠的进食量和体重增长均无影响,对肝肾功能均未发现明显毒性作用,对血常规、血生化、尿液生化及骨髓片等均未见明显影响。
喂养4周后取双侧股骨,右侧进行骨钙测定,左侧进行骨密度测定。骨钙采用原子吸收法测定,骨密度采用固体密度仪测定仪法测定。结果如下表所示。
表1大鼠饲喂实验
组别 | 骨钙 | 骨密度 |
低钙饲料组 | 53.27±7.41 | 0.182±0.003 |
实施例1剂量组 | 76.31±3.28 | 0.263±0.007 |
实施例1高剂量组 | 88.76±5.33 | 0.286±0.006 |
对比例1剂量组 | 69.28±2.00 | 0.216±0.003 |
对比例2剂量组 | 55.36±3.12 | 0.191±0.005 |
对比例3剂量组 | 50.86±3.62 | 0.178±0.006 |
由表中数据可得,实验组骨钙、骨密度含量均高于对照组和对比组,对于骨密度增强效果明显;不仅组份的变化会对骨增强效果有硬性,而且组分配比的变化也会产生影响。
实施例8人体服用效果实验
选取年龄50-70阶段,男性女性分别20人,20人中具有腕关节疼、膝关节疼各10人,以上病人不排除具有糖尿病,高血压的病人等其余病症。按照实施例2进行服用4个月。经服用后,女性腕关节疼痛改善的有6人,膝关节疼痛改善的9人;男性腕关节疼痛改善的7人,膝关节改善的9人。
随访受试者,服用本发明组合物后,缓解疼痛起效时间段,比服用氨基葡萄糖加硫酸软骨素减少1-3天,并且缓解周期(疼痛缓解时间间隔)明显缩短1-2月。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术的技术人员在本发明批露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。
Claims (10)
1.一种增强骨密度缓解中老年关节疼痛的组合物,该组合物的组分及重量份为:
大豆肽5~10份、硫酸软骨素0.2~0.5份、氨基葡萄糖或其盐0.5~1.5份、低聚木糖0.7~3份、钙吸收促进剂及钙质补充剂0.8-1.3份、活血化瘀性质中药提取物0.5-3份、大豆肽苦味掩盖剂3-10份。
2.根据权利要求1所述的组合物,其特征在于,所述钙吸收促进剂选自维生素D、乳糖、赖氨酸中的一种或几种。
3.根据权利要求1所述的组合物,其特征在于,所述钙质补充剂选自葡萄糖酸钙、碳酸钙、乳酸钙、柠檬酸钙中的一种或几种。
4.根据权利要求1所述的组合物,其特征在于,所述活血化瘀性质中药提取物选自红花提取物、三七提取物、川芎提取物。
5.根据权利要求1所述的组合物,其特征在于,大豆肽苦味掩盖剂选自阿拉伯糖、木糖醇、柠檬酸、苹果酸中的一种或几种。
6.根据权利要求1所述的组合物,其特征在于,组合物的组分及重量份为:大豆肽5~10份、硫酸软骨素0.2~0.5份、硫酸氨基葡萄糖0.5~1.5份、低聚木糖0.7~3份、维生素D0.8-3×10-5份、乳酸钙0.8-1.2份、红花提取物0.5-3份、阿拉伯糖0.5~1.5份、木糖醇3~8份。
7.权利要求1-6任一项所述组合物在制备缓解和/预防或治疗中老年关节疼痛的食品、药品或保健品中的应用。
8.一种缓解和/预防或治疗中老年关节疼痛的食品,所述食品的有效成分为权利要求1-6任一项所述组合物。
9.一种缓解和/预防或治疗中老年关节疼痛的保健品或药品,所述保健品或药品的有效成分为权利要求1-6任一项所述组合物。
10.根据权利要求9所述所述保健品或药品,其特征在于,除有效成分外,还可以包括常规的辅料成分,选自硬脂酸镁、羧甲基纤维素钠、二氧化硅、滑石粉、聚乙二醇或微晶纤维素;所述保健品或药品可制成液体冲剂、粉剂、片剂、胶囊剂或其他常规剂型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610621668.7A CN106262809A (zh) | 2016-07-29 | 2016-07-29 | 一种增强骨密度缓解中老年关节疼痛的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610621668.7A CN106262809A (zh) | 2016-07-29 | 2016-07-29 | 一种增强骨密度缓解中老年关节疼痛的组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106262809A true CN106262809A (zh) | 2017-01-04 |
Family
ID=57664060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610621668.7A Pending CN106262809A (zh) | 2016-07-29 | 2016-07-29 | 一种增强骨密度缓解中老年关节疼痛的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106262809A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106820136A (zh) * | 2017-03-06 | 2017-06-13 | 青岛海大华旗生物科技有限公司 | 一种改善睡眠质量的组合物及其制备方法 |
CN106880054A (zh) * | 2017-03-06 | 2017-06-23 | 青岛海大华旗生物科技有限公司 | 一种预防和治疗肌肉萎缩症的保健食品及其制备方法 |
CN108433110A (zh) * | 2018-06-06 | 2018-08-24 | 广州富诺健康科技股份有限公司 | 以乳矿物盐为原料的增加骨密度的片剂及其制备方法 |
CN114732131A (zh) * | 2022-04-19 | 2022-07-12 | 山东焦点福瑞达生物股份有限公司 | 一种用于预防和缓解关节疾病的复合透明质酸组合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101322551A (zh) * | 2007-08-31 | 2008-12-17 | 辽源雷霓森药业有限公司 | 一种用于增加骨密度和修复关节软骨的组合物 |
CN101773539A (zh) * | 2009-09-04 | 2010-07-14 | 上海春芝堂生物制品有限公司 | 一种具有缓解和治疗骨关节病功能的配方 |
CN102423035A (zh) * | 2011-11-25 | 2012-04-25 | 苏州先阔生物科技有限公司 | 一种用于辅助治疗中老年退行性骨关节疾病的含低聚木糖的保健食品 |
CN103082276A (zh) * | 2011-10-28 | 2013-05-08 | 北京康比特体育科技股份有限公司 | 一种用于减少和促进运动损伤修复的组合物 |
CN104188999A (zh) * | 2014-08-13 | 2014-12-10 | 哈药集团制药六厂 | 一种具有增加骨密度、改善骨骼及关节功能的组合物及其制备方法 |
-
2016
- 2016-07-29 CN CN201610621668.7A patent/CN106262809A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101322551A (zh) * | 2007-08-31 | 2008-12-17 | 辽源雷霓森药业有限公司 | 一种用于增加骨密度和修复关节软骨的组合物 |
CN101773539A (zh) * | 2009-09-04 | 2010-07-14 | 上海春芝堂生物制品有限公司 | 一种具有缓解和治疗骨关节病功能的配方 |
CN103082276A (zh) * | 2011-10-28 | 2013-05-08 | 北京康比特体育科技股份有限公司 | 一种用于减少和促进运动损伤修复的组合物 |
CN102423035A (zh) * | 2011-11-25 | 2012-04-25 | 苏州先阔生物科技有限公司 | 一种用于辅助治疗中老年退行性骨关节疾病的含低聚木糖的保健食品 |
CN104188999A (zh) * | 2014-08-13 | 2014-12-10 | 哈药集团制药六厂 | 一种具有增加骨密度、改善骨骼及关节功能的组合物及其制备方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106820136A (zh) * | 2017-03-06 | 2017-06-13 | 青岛海大华旗生物科技有限公司 | 一种改善睡眠质量的组合物及其制备方法 |
CN106880054A (zh) * | 2017-03-06 | 2017-06-23 | 青岛海大华旗生物科技有限公司 | 一种预防和治疗肌肉萎缩症的保健食品及其制备方法 |
CN108433110A (zh) * | 2018-06-06 | 2018-08-24 | 广州富诺健康科技股份有限公司 | 以乳矿物盐为原料的增加骨密度的片剂及其制备方法 |
CN114732131A (zh) * | 2022-04-19 | 2022-07-12 | 山东焦点福瑞达生物股份有限公司 | 一种用于预防和缓解关节疾病的复合透明质酸组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6224871B1 (en) | Dietary supplement for nutritionally promoting healthy joint function | |
Bland | Canine osteoarthritis and treatments: a review | |
US20070004629A1 (en) | K9 and equine joint health food supplement and method of administering | |
CN104188999A (zh) | 一种具有增加骨密度、改善骨骼及关节功能的组合物及其制备方法 | |
US20140287058A1 (en) | Composition for maintaining bone health and for treating osteoarthritis and osteoarthrosis of the joints | |
CN106794196A (zh) | 用于预防和治疗关节疼痛的组合物及其制备方法 | |
CN109567157A (zh) | 一种用于改善骨关节健康的组合物及其制备方法 | |
CN106262809A (zh) | 一种增强骨密度缓解中老年关节疼痛的组合物 | |
CN106072651B (zh) | 一种具有增加骨密度、抗炎镇痛作用的组合物及其制备方法 | |
CN104758360B (zh) | 一种增加骨密度的组合物 | |
CN110859247A (zh) | 组合物、制备方法及其在制备治疗宠物关节疾病药品、保健品及食品中的应用 | |
CN102423487A (zh) | 一种骨关节保健组合物及其应用 | |
CN108112997B (zh) | 一种保健食品组合物 | |
CN108741099A (zh) | 一种有助于关节舒适的营养组合物及其制备方法和应用 | |
RU2454999C2 (ru) | Лекарственное средство, применяющееся при поражениях хряща | |
CN109453342A (zh) | 一种具有关节保护功效的中药组合物及应用、制备方法、保健食品 | |
CN107823634A (zh) | 基于海洋多糖的治疗骨质疏松药物 | |
US20080312149A1 (en) | Health Food and Pharmaceutical Composition for Amelioration of Disease Induced by Metabolic Disorder in Cartilage | |
WO2021042275A1 (zh) | 一种治疗骨性关节炎的的中药组合物 | |
JP2001346545A (ja) | 栄養補助食品 | |
JP2003335698A (ja) | 高尿酸血症治療又は予防用組成物 | |
WO2016043668A1 (en) | A composition suitable for vegetarians providing calcium supplementation as well as gout prevention and treatment and the method of preparation thereof | |
CN105831738A (zh) | 一种多肽氨糖软骨素营养健康食品 | |
JP2005232089A (ja) | 骨量増加作用を有する機能性経口投与剤 | |
WO2021042276A1 (zh) | 一种治疗骨性关节炎的联合用药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
RJ01 | Rejection of invention patent application after publication |